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Abstract: Experiments carried out with cultured cells and in experimental animals have 
consistently shown that phospholipids (PLs) can inhibit intestinal cholesterol absorption. 
Limited evidence from clinical studies suggests that dietary PL supplementation has a 
similar effect in man. A number of biological mechanisms have been proposed in order to 
explain how PL in the gut lumen is able to affect cholesterol uptake by the gut mucosa. 
Further research is however required to establish whether the ability of PLs to inhibit 
cholesterol absorption is of therapeutic benefit. 
Keywords:  cardiovascular disease; cholesterol; intestine; micelle; phosphatidylcholine; 




HDL, high-density lipoprotein; LDL, low-density lipoprotein; lysoPC, lysophosphatidylcholine; 
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An increased concentration of cholesterol in the blood (i.e., hypercholesterolemia) is widely 
recognized as a risk factor for coronary artery disease. Reducing plasma levels of total and low-density 
lipoprotein (LDL) cholesterol by diet, drugs or lifestyle modification is thus of principal importance in 
treating and preventing cardiovascular disease. In humans, blood cholesterol is derived from two 
sources. It is either absorbed from the diet by the intestine, or it is synthesized from precursor 
molecules in the liver. Hepatic cholesterol synthesis can be pharmacologically regulated with statins 
by inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase, the enzyme responsible for cholesterol 
synthesis. Statins are very potent lipid-lowering agents and they have been shown to significantly 
reduce coronary morbidity and mortality [1]. Many patients do not however reach currently defined 
treatment goals and there is considerable interest in finding additional ways to reduce plasma and LDL 
cholesterol levels. This has led to the development of a new family of drugs that inhibits intestinal 
cholesterol absorption. Ezetimibe is a 2-azetidinone compound that reduces cholesterol absorption by 
inhibiting the protein responsible for cholesterol transport into enterocytes lining the gut lumen, i.e., 
Niemann-Pick C1-Like1 (NPC1L1) protein. As monotherapy, ezetimibe decreases LDL-C levels by 
15–20 percent [2]; in combination with statins it reduces LDL-C by an additional 20–25% [3]. 
Increasing use of these therapeutic agents has refocussed interest on foods and food components that 
have the potential to reduce intestinal cholesterol absorption. They include plant sterols, soluble fibres, 
and saponins [4], which reduce plasma cholesterol and LDL-cholesterol levels by interfering with 
intestinal cholesterol and bile acid uptake. Different types of phospholipids (PLs) have also been 
shown to inhibit intestinal cholesterol absorption and the aim of this article is to review our current 
understanding of the effects of dietary PLs on intestinal cholesterol metabolism. 
 
2. Phospholipid Intake in Humans 
 
 The normal dietary intake of PL is 2–8 grams per day, which represents 1–10% of total daily fat 
intake. Foods with a high PL content include eggs, organ and lean meats, fish, shellfish, cereal grains 
and oilseeds. Leafy vegetables, fruits and tubers, on the other hand, contain relatively low levels 
(Table 1) [5]. The most common PL in food is phosphatidylcholine (PC) while other PLs, such as 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI) are present in 
much smaller amounts. Sphingomyelin (SM), a phosphorus-containing lipid (more accurately 
described as a sphingolipid), is present in eggs, meat and fish and is ingested at a level of 0.3–0.4 
grams per day. Production of low-fat food products has generally led to a reduction in dietary PL 
intake. It must not be overlooked however that PL (referred to as lecithin in commercial circles, i.e., a 
mixture of PC, PE and PI), is widely used as a food additive. Lecithin is a standard ingredient in 
margarine, and provides consistency of texture to dressings and other creamy products. It acts as an 
important emulsifier in the manufacture of chocolate and aids in the dispersibility of food powders 
(e.g., cocoa and whole milk powders). Lecithin is also frequently used as a tin or mould release agent 
in the bakery and confectionery industry, and can form complexes with starch to improve crumb 
softness and shelf life of bread. Although levels of lecithin in processed foods are generally low (0.5% 
or less), their widespread consumption implies that the amount of PL ingested in this form is   
not negligible. Nutrients 2010, 2                              
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Table 1. Total lipid and phospholipid content of specific foods. 




  Total PL  PC  PE  PI  PS  SM  lysoPC 
Egg Yolk  31.8  10,306  6,771  1,917  64  -  486  419 
Pig  Liver  3.7  2,901  1,688  618  209 38 131 61 
Chicken  Liver 5.6  2,542  1,120  829 - 146  291 - 
Soybeans 20.8  2,308  9,17  536  287  - - - 
Squid  1.68 1,098  777  114 -  83  102 - 
Chicken  Breast  1.12  782  391  187 - 100  56  - 
Beef 4.1  660  407  207  -  -  46  - 
Peanuts 48.5  620  270  50  150  -  -  - 
Cod 2.2  580  331  128  23  29  29  6 
Spinach 0.3  157  37  36  11  -  -  - 
Potato 0.15  76  38  22  12  1  -  - 
Carrot 0.3  55  23  15  5  3  -  - 
Apple 0.09  40  21  10  6  1  -  - 
Cow’s Milk  3.7  34  12  10  2  1  9  - 
Abbreviations: PL, phospholipid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, 
phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin; lysoPC, lysophosphatidyl-
choline (taken from ref. [5]). 
 
3. Phospholipid Digestion and Absorption 
 
The predominant PL in the intestinal lumen is PC, which is the second most abundant lipid in the 
digestive tract after triglyceride [6]. PC is derived not only from the diet but also from the bile. In fact, 
the biliary pathway delivers 10–20 g of PL and ~1.5 g of cholesterol to the intestinal lumen per day, 
which is at least two to four times more than that supplied by the diet. Dietary PC is almost completely 
absorbed (>90%) by the human intestine, and rapidly appears in plasma lipoproteins and red blood 
cells [7]. PC digestion occurs in the small intestine, since lingual and gastric lipases are incapable of 
hydrolyzing PC. Chemical breakdown of PLs is carried out primarily by pancreatic phospholipase A2 
(PLA2) and other lipases secreted by the pancreas in response to food intake [8]. PLA2 is secreted as an 
anionic zymogen. It is activated by trypsin cleavage and its activity requires the presence of bile salts. 
It interacts with PLs at the sn-2 position to yield free fatty acid and lysoPC. Both components are taken 
up by mucosal cells and are resecreted within chylomicrons as newly-formed PL or triglyceride. A 
proportion of chylomicron PL is subsequently transferred to high-density lipoproteins (HDL), which 
occurs relatively rapidly, i.e., within 5-6 hours of PL ingestion [9]. Deacylation of lysoPC in the gut 
lumen is believed to be quite limited and the majority of PL uptake is thus as lysoPC and free fatty 
acid. Surprisingly, mice deficient in PLA2 display no abnormality in dietary PL or triglyceride 
absorption, suggesting that PLA2 may not be essential for PL digestion and that other enzymes can 
compensate for lack of PLA2-mediated PL hydrolysis [10].  
It is estimated that an adult human on a Western diet ingests 0.3–0.4 grams of sphingolipids per  
day [11]. Only a proportion of this is SM, which means that less than 5% of dietary PL is SM. 
Furthermore, very little dietary SM directly contributes to plasma pools of this PL. The major enzymes Nutrients 2010, 2                              
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responsible for SM degradation in the intestinal lumen and mucosa are alkaline SMase and neutral 
ceramidase. These enzymes are located in the surface membrane of mucosal cells with catalytic 
domains facing the outside of the cell. They are responsible for the conversion of SM to ceramide and 
subsequently to sphingosine and palmitic acid. Ceramide is incompletely absorbed and increasing 
amounts of SM in the diet leads to an increased proportion of ceramide in the feces [11]. 
 
4. Cholesterol Absorption 
 
Cholesterol in the gut lumen is derived from the diet (~400 mg/day) and from the bile (~1 g/day). In 
humans, cholesterol absorption is not complete and on average half of the cholesterol in the gut lumen 
is absorbed and the remainder is excreted in the faeces. This varies widely between individuals 
however, and percent absorption varies from 15 to 75% [12]. Individuals also respond differently to 
changes in dietary cholesterol reflecting the fact that both metabolic and genetic factors regulate 
cholesterol absorption. The solubilization of cholesterol is very poor in the aqueous environment of the 
gut and its digestion and absorption is dependent on partitioning into bile micelles. Only nonesterified 
cholesterol can be incorporated into bile acid micelles and any esterified cholesterol in the diet   
(10–15% of total) must be hydrolyzed by cholesterol esterase. Mixed micelles thus contain bile acids, 
free cholesterol and PL, together with triglyceride, monoacylglyceride, fatty acids and 
lysophospholipids. These lipid complexes facilitate the transport of cholesterol across the unstirred 
water layer, which is a diffusional barrier at the intestinal lumen-enterocyte interface. The exact 
mechanism by which unesterified cholesterol subsequently crosses the brush-border membrane in 
micelles and is taken up by the mucosal cell remains unclear. For many years, cholesterol absorption 
was believed to be a simple, energy-independent, passive diffusion process [13]. Cholesterol is 
absorbed much more efficiently than structurally-related plant sterols however, suggesting that a 
facilitated mechanism is involved. Three proteins have thus been identified which are believed to be 
key players in the control of cholesterol absorption, i.e., the cholesterol uptake transporter, Niemann-
Pick C1 like 1 (NPC1L1) [14], and the cholesterol efflux transporters: ATP-binding cassette (ABC) 
proteins ABCG5 and ABCG8 [15].  
 
5. Phospholipid Effects on Cholesterol Absorption 
 
It is well accepted that the aqueous solubility of cholesterol is extremely low. The transport of 
cholesterol from the lipid-rich milieu of the intestinal contents to mucosal cells lining the gut lumen is 
therefore directly dependent on emulsification and micellar solubilization by the detergent-like 
properties of biliary lipids and the products of dietary lipid lipolysis [16]. Biliary PC is of central 
importance in this process and cholesterol cannot be effectively solubilized in bile without biliary  
PC [17]. Thus intestinal cholesterol absorption relies on adequate amounts of PL in the gut lumen. 
Contrary to expectation, an excess of PL leads to suppression of cholesterol absorption. 
Evidence for the ability of PL to inhibit intestinal cholesterol absorption was first provided by 
Alfred Rampone from the University of Oregon [18]. Bile was known to be essential for cholesterol 
absorption. The existence of an additional active component in bile was however established when it 
was shown that uptake of micellar lipids by everted rat intestinal sacs in vitro was increased by added Nutrients 2010, 2                              
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bile acid salts but not by whole bile. It was suggested that the inhibitory non-bile salt component might 
be lecithin and experiments were carried out demonstrating that increasing concentrations of liver 
lecithin retarded the intestinal uptake of cholesterol [19]. Greater than 50% suppression of cholesterol 
uptake was observed with the addition of 15 mg (0.8 mM) lecithin, and egg lecithin at a dose of 30mg 
was found to have a similar effect as a 30 mg dose of liver lecithin (Figure 1).  
Experiments with radioactively labeled lipids and everted rat jejunal gut sacs were subsequently 
carried out by Rodgers and O’Connor [20]. Dilinoleoyl phosphatidylcholine significantly reduced 
intestinal uptake of both [
14C]oleic acid (28% at 2.0 mM) and [
3H] cholesterol (41% at 2.0 mM). 
Reduced uptake was not observed with lysoPC, giving rise to the concept that intact PL needed to be 
present in the gut lumen in order to maintain an effect on cholesterol absorption. It was hypothesized 
that conversion of PC to lysoPC led to rapid uptake of the lysoPC and disappearance of any inhibitory 
effect. This was supported by experiments in anaesthetized animals, in which dipalmityl 
phosphatidylcholine, added to mixed micelles as a diether (i.e., a form resistant to hydrolysis by 
pancreatic lipase) inhibited intestinal uptake of [
14C]oleic acid and [
3H]cholesterol. Further 
experiments in bile duct-cannulated rats demonstrated that diether PC impaired intestinal absorption of 
cholesterol to a greater extent than naturally-occurring diester PC in the absence of any significant 
effect on the absorption of bile salts [21,22]. 
A number of studies in whole animals have confirmed that native PC exerts an inhibitory effect on 
intestinal cholesterol absorption. Hollander and Morgan, using a single pass bile-diverted perfusion 
system in unanaesthetised rats, showed that lecithin (l--lecithin) reduced cholesterol absorption in a 
dose-dependent fashion (i.e., 44, 52 and 54% at doses of 0.5, 1.0 and 1.5 mM respectively) [23]. The 
absorption, metabolism and excretion of cholesterol was subsequently investigated by O’Mullane and 
Hawthorne in rats fed diets supplemented with unsaturated lecithin or unsaturated triglyceride [24]. 
Animals were maintained for 6 weeks on synthetic diets containing 0.5% cholesterol and either 4% by 
wt corn oil or 6% soya lecithin (providing similar amounts of linoleic acid). Cholesterol absorption 
measured with a dual isotope ratio method was significantly lower in soya lecithin vs. corn oil groups 
(41.8 ± 4.6% vs. 59.7 ± 14.9%, P < 0.02). At the same time, fecal output of neutral sterol was 
significantly higher in soya lecithin-fed animals (22.5 v 15.6 mg/day, P < 0.05), providing support for 
the concept that dietary PC can reduce intestinal cholesterol uptake independent of its linoleic fatty 
acid content. 
The intestinal effects of different forms of PC have been investigated by Jiang et al. [25]. Lipid 
emulsions containing [
14C]cholesterol were infused via a duodenal catheter into mesenteric lymph duct 
cannulated rats and the effects of egg PC (EPC), hydrogenated EPC and soy PC (SPC) on the 
lymphatic appearance of radioactively-labeled cholesterol were compared. SPC had little effect on 
intestinal cholesterol absorption, whereas egg PC reduced absorption by 20%. The inhibitory effect of 
hydrogenated EPC was greater than native EPC, suggesting that increased saturation of PL fatty acid 
acyl groups led to greater inhibition of cholesterol absorption [25]. Intraduodenal infusion of egg 
sphingomyelin (SM) has also been shown to cause a dose-dependent reduction in the appearance of 
lymphatic cholesterol. SM lowered the intestinal absorption of cholesterol, alpha-tocopherol and fatty 
acid but not retinol [26]. Furthermore, milk SM containing fatty acids with a higher degree of 
saturation and longer chain length was more effective than egg SM in inhibiting cholesterol   
absorption [27]. Interestingly, egg SM given orally for periods of three weeks at doses of 0.2 and 0.4% Nutrients 2010, 2                              
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has been found to significantly reduce plasma triglyceride and cholesterol levels in APOE*3Leiden mice 
fed a Western-type diet. Phytosphingosine, a sphingolipid similar in structure to SM, decreased the 
absorption of dietary cholesterol and free fatty acids in these animals by 50% and 40% respectively [28]. 
Figure 1. Effect of liver lecithin on intestinal uptake of micellar cholesterol. Everted rat 
gut sacs were incubated at 37 
oC for 1 hr in 25ml micellar solution containing 0.15 mM 
cholesterol and 4.8 mM bile salt with various amounts of added lecithin. Orange ring 
symbol represents data obtained with egg lecithin replacing liver lecithin. Each point is the 
mean of 4–8 experiments. Vertical bars are SE (reproduced from ref. [18]). 
       
Although there is good evidence demonstrating an effect of PL on intestinal cholesterol absorption 
in experimental animals, only a limited number of studies have been carried out in humans. The first of 
these was conducted by Beil and Grundy [29], who infused human subjects with intraduodenal lecithin 
or safflower oil with similar fatty acid compositions. The primary objective was to determine whether 
large amounts of dietary lecithin in the absence of triglyceride could induce the formation of 
chylomicrons. This was indeed shown to be the case, however a secondary objective was the 
measurement of cholesterol absorption, which was estimated by measuring the difference in luminal 
cholesterol concentration at distances 10 cm and 50 cm downstream of the infusion site. The relatively 
large amount of PL that was infused luminally (150 mg/kg/hr) not only blocked absorption but actually 
“extracted” cholesterol from the intestinal mucosa, resulting in ‘negative’ absorption values of −45 ± 
2% compared to 40 ± 4% obtained in control subjects. 
A less invasive and more physiological assessment was carried out by the same laboratory several 
years later [30]. In this study, 10 hypertriglyceridemic patients (nine men and one woman) were 
treated for five weeks with orally administered safflower oil (7 grams/day), followed by five weeks of 
treatment with lecithin (10 grams/day). The amount and type of fatty acids in the two oral supplements Nutrients 2010, 2                              
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(given as a single dose each morning) were similar. Cholesterol adsorption was measured during the 
2
nd or 3
rd week of each treatment in seven patients. Although lecithin treatment had no discernible 
effect on plasma lipid levels, it significantly increased the molar percent of bile acids and decreased 
the molar percent of lecithin in gall bladder bile. It also had a small but significant inhibitory effect on 
cholesterol absorption (42 ± 2% v 36 ± 2%, P < 0.05) (Figure 2).  
Figure 2. Effect of dietary lecithin (polyenylphosphatidylcholine, 10 grams/day) on 
cholesterol absorption in hypertriglyceridemic patients. Data are shown for individual 
patients. During Period I patients were given 7 grams/day of safflower oil and during 
Period 2 they were given 10 grams/day lecithin (one dose each morning). The amount and 
composition of fatty acids was equivalent for the two treatments. Cholesterol absorption 
was measured after two or three weeks by monitoring the ratio of [
14C] cholesterol to [
3H] 
b-sitosterol in stools of patients given oral radioactive sterols. Mean cholesterol absorption 
(shown by the dark horizontal line) during the control period was 42 ± 2% and during the 
lecithin treatment period was 36 ± 2%. (reproduced from ref. [30]) 
 
 
A third study investigated the effect of orally administered lecithin on plasma and whole body lipid 
metabolism in two normolipidemic subjects and six patients with familial hypercholesterolemia [31]. 
A fat-modified diet was given for 10 days before 10 grams of polyunsaturated fatty acids (PUFA) were 
replaced for a further period of 10 days by 18 grams of polyunsaturated PC. The two dietary regimes 
contained similar calories, and similar amounts of cholesterol and polyunsaturated fatty acids. No Nutrients 2010, 2                              
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significant change was observed in total plasma triglyceride, cholesterol or PL levels when PC was 
added to the diet. Similarly, no significant change occurred in LDL or HDL cholesterol concentrations. 
In contrast, fecal sterol analysis in six individuals revealed a consistent increase in fecal neutral sterol 
excretion (69%) and a negative sterol balance (−1,362 ± 232 vs. −793 ± 222 mg/day) during the PC vs. 
PUFA supplementation periods. No evidence was found for a change in the concentration of bile acids, 
PL or cholesterol in bile. Thus, although cholesterol absorption was not measured directly, indirect 
evidence was obtained for reduced intestinal cholesterol uptake during PC supplementation. 
 
6. Mechanisms for the Inhibitory Effect of PL on Cholesterol Absorption 
 
The aforementioned studies provide consistent evidence that intestinal PLs affect cholesterol uptake 
from the gut lumen and that dietary PL supplementation can lead to reduced intestinal cholesterol 
absorption. This raises a fundamental question as to how this biological effect might be mediated.  
There are at least three possible mechanisms (Table 2) that together or alone could explain the 
effects of luminal PL on intestinal cholesterol absorption. The first possibility is that excess PL 
interferes with efficient micellar PL hydrolysis, which is a prerequisite for efficient mucosal uptake of 
cholesterol. Support for this concept is based on the fact that pancreatic secretions are known to be 
critical for fat absorption, i.e., fat and cholesterol absorption is significantly increased when patients 
with pancreatic insufficiency are given pancreatic enzymes as a dietary supplement [32]. Bile salt-
stimulated carboxyl ester lipase (CEL), also called cholesterol esterase, is one of the major proteins 
secreted by the pancreas. It has a wide substrate specificity hydrolyzing cholesterol esters, tri-, di- and 
monoglycerides, and phospholipids [33]. CEL was originally thought to be an important mediator of 
dietary cholesterol absorption, however, more recent evidence points to a critical role of phospholipase 
A2 (pPLA2). The effect of pPLA2 and micellar PL composition on the uptake and metabolism of lipids 
has been examined in human intestinal Caco-2 cells [34]. PC-containing micelles, though not those 
containing lysoPC, reduced the uptake, esterification and secretion of cholesterol with little effect on 
oleic acid absorption. Substitution of half or more of the PC with lysoPC reversed the PC-dependent 
inhibition. pPLA2 also enhanced cholesterol absorption and pPLA2-dependent increase in cholesterol 
absorption was inhibited by a pPLA2 inhibitor. Anti-PLA2 antibodies have in turn been shown to 
completely abolish the ability of porcine pancreatic extract to facilitate cholesterol uptake by Caco-2 
cells [35], and the PLA2 inhibitor (FPL 67047XX) has been shown to retard cholesterol absorption in 
rats [10]. Together, these data support the concept that absorption of micellar cholesterol by intestinal 
cells is dependent on elimination of micellar PC and that inhibition of PL hydrolysis leads to reduced 
cholesterol uptake. One can thus speculate that increased dietary PL may impede or delay normal 
phospholipase-driven hydrolysis of micellar PL with subsequent downstream effects on   
cholesterol absorption. Nutrients 2010, 2                              
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Table 2. Possible mechanisms for inhibition of cholesterol absorption by phospholipid. 
1.  excess PL interferes with efficient micellar PL hydrolysis - a prerequisite for mucosal uptake 
of cholesterol 
2.  surplus PL alters the physicochemical properties of mixed micelles (i.e., their size, 
composition and/or biological characteristics) resulting in reduced absorption of cholesterol 
3.  PL acts on the membrane characteristics of enterocytes or has a direct effect on cellular 
cholesterol transporters that regulate intestinal cholesterol uptake 
 
Cholesterol bioavailability in the intestinal lumen could potentially be reduced by excess PL via a 
second mechanism. It is feasible that surplus PL could affect the physicochemical properties of mixed 
micelles (i.e., their size, composition and/or biological characteristics). PL could induce a shift of 
cholesterol molecules from the micellar phase into lamellar (vesicular) phase from which cholesterol is 
poorly absorbed - a scenario based on the sequential steps of fat digestion described by   
Hernell  et al. [36]. This model proposes that crude emulsion particles containing predominantly 
triglyceride enter the duodenum from the stomach. Biliary lipids in various physical states (simple 
micelles, mixed micelles and vesicles), together with pancreatic lipase and colipase, adsorb to the 
surface of emulsion particles and lipolysis commences. Lipolytic products are generated and 
accumulate on the surface of emulsion particles. Increasing amounts of fatty acid and monoglyceride 
(in the presence of optimal concentrations of bile salts and PL) leads to surface pressures that cause 
surface lipids to bud off as unilamellar vesicles. These vesicles are converted to micelles in the 
presence of bile salts and are the ideal physical form for maximal cellular uptake of fatty acids, 
monoglyceride and cholesterol. It can be speculated that excess PL may impede the conversion of 
vesicles to micelles. Alternatively, different dietary PLs could reduce micellar solubility of cholesterol 
thereby impeding the transport of cholesterol to the intestinal mucosa. This possibility is supported by 
work from Martin Carey’s laboratory in Boston showing that PL acyl chain unsaturation modulates the 
distribution of lecithin molecular species between mixed micelles and vesicles in model bile [37,38]. 
Different biochemical techniques revealed that apparent micellar cholesterol solubilities and meta-
stable vesicle cholesterol/lecithin molar ratios were 60%  and 100% higher, respectively, in bile 
composed of unsaturated lecithins. At the same time, systems composed of sphingomyelin or the 
saturated PC dipalmitoyl phosphatidylcholine (DPPC, 16:0–16:0 PC) had poorer cholesterol-
solubilizing capacity [39]. Cholesterol uptake by Caco-2 cells was in turn reduced in the presence of 
milk sphingomyelin, and addition of 0.5% wt/wt milk SM or DPPC to the diet of mice for four days 
resulted in a significant reduction in cholesterol absorption. The ability of SM to reduce cholesterol 
absorption has been supported by several studies in rats [26,27,40]. As mentioned earlier, milk SM 
(containing fatty acids with a higher degree of saturation and longer chain length) was found to be 
more effective than egg SM in inhibiting cholesterol absorption [27], which supports the concept that 
the amount and type of SM in the gut lumen can affect the physicochemical characteristics and 
metabolism of luminal micelles. 
A third mechanism pertains to a direct effect of PLs on enterocytes themselves. One can speculate 
that PLs in the gut lumen may affect the membrane characteristics of enterocytes or have a direct 
effect on cellular cholesterol transporters thus affecting intestinal cholesterol uptake. Although there is 
limited data to directly support this mechanism, it is well known that the biological function of cell Nutrients 2010, 2                              
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membranes is very dependent on component PLs and their interaction with intramembrane sterols 
[41]. Furthermore, the activity of membrane proteins is directly affected by their interaction with 
membrane PLs [42]. It is thus feasible that dietary PLs could have a direct effect on the absorptive 
capacity of enterocytes lining the gut lumen.  
 
7. Summary and Conclusions  
 
Both in vitro and in vivo studies have consistently demonstrated that PLs can inhibit intestinal 
cholesterol absorption. A number of biological mechanisms have subsequently been proposed to 
explain how the amount and type of PL in the gut lumen is able to affect cholesterol uptake. Further 
research is however required to define the extent to which cholesterol absorption can be influenced by 
dietary PLs in different subjects and different patient groups. The degree to which this biological 
activity is associated with an effect on plasma lipid levels [43] or hepatic lipid levels [44] needs further 
investigation. This work will be critical in establishing whether the ability of PLs to inhibit cholesterol 




1.  Brugts, J.J.; Yetgin, T.; Hoeks, S.E.; Gotto, A.M.; Shepherd, J.; Westendorp, R.G.; de Craen, A.J.; 
Knopp, R.H.; Nakamura, H.; Ridker, P.; van Domburg, R.; Deckers, J.W. The benefits of statins 
in people without established cardiovascular disease but with cardiovascular risk factors: meta-
analysis of randomised controlled trials. BMJ 2009, 338, b2376. 
2.  Pandor, A.; Ara, R.M.; Tumur, I.; Wilkinson, A.J.; Paisley, S.; Duenas, A.; Durrington, P.N.; 
Chilcott, J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review 
and meta-analysis of randomized controlled trials. J. Intern. Med. 2009, 265, 568-580. 
3.  Mikhailidis, D.P.; Sibbring, G.C.; Ballantyne, C.M.; Davies, G.M.; Catapano, A.L. Meta-analysis 
of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. 
Opin. 2007, 23, 2009-2026. 
4.  Carr, T.P.; Jesch, E.D. Food components that reduce cholesterol absorption. Adv. Food Nutr. Res. 
2006, 51,165-204. 
5.  Weihrauch, J.L.; Son, Y.S. The phospholipid content of foods. JAOCS 1983, 60, 1971-1978. 
6.  Phan, C.T.; Tso, P. Intestinal lipid absorption and transport. Front Biosci. 2001, 6, D299-319.  
7.  Zierenberg, O.; Grundy, S.M. Intestinal absorption of polyenephosphatidylcholine in man. J. 
Lipid Res. 1982, 23, 1136-1142. 
8.  van den Bosch, H.; Postema, N.M.; de Haas, G.H.; van Deenen, L.L. On the positional specificity 
of phospholipase A from pancreas. Biochim. Biophys. Acta 1965, 98, 657-659. 
9.  Tall, A.R.; Blum, C.B.; Grundy, S.M. Incorporation of radioactive phospholipid into subclasses of 
high-density lipoproteins. Am. J. Physiol. 1983, 244, E513-E516. 
10.  Richmond, B.L.; Boileau, A.C.; Zheng, S.; Huggins, K.W.; Granholm, N.A.; Tso, P.; Hui, D.Y. 
Compensatory phospholipid digestion is required for cholesterol absorption in pancreatic 
phospholipase A(2)-deficient mice. Gastroenterology 2001, 120, 1193-1202. Nutrients 2010, 2                              
 
126
11.  Duan, R.D.; Nilsson, A. Metabolism of sphingolipids in the gut and its relation to inflammation 
and cancer development. Prog. Lipid Res. 2009, 48, 62-72. 
12.  Grundy, S.M. Absorption and metabolism of dietary cholesterol. Annu. Rev. Nutr. 1983, 3, 71-96. 
13.  Wilson, M.D.; Rudel, L.L. Review of cholesterol absorption with emphasis on dietary and biliary 
cholesterol. J. Lipid Res. 1994, 35, 943-955. 
14.    Davis, H.R., Jr.; Altmann, S.W. Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol 
transporter. Biochim. Biophys. Acta 2009, 1791, 679-683. 
15. Sabeva, N.S.; Liu, J.; Graf, G.A. The ABCG5 ABCG8 sterol transporter and phytosterols: 
implications for cardiometabolic disease. Curr. Opin. Endocrinol. Diabetes Obes. 2009,  16,  
172-177. 
16.  Iqbal, J.; Hussain, M.M. Intestinal lipid absorption. Am. J. Physiol. Endocrinol. Metab. 2009, 296, 
E1183-E1194. 
17.  Carey, M.C.; Small, D.M. The physical chemistry of cholesterol solubility in bile. Relationship to 
gallstone formation and dissolution in man. J. Clin. Invest. 1978, 61, 998-1026. 
18.  Rampone, A.J. The effects of bile salt and raw bile on the intestinal absorption of micellar fatty 
acid in the rat in vitro. J. Physiol. 1972, 222, 679-690. 
19.  Rampone, A.J. The effect of lecithin on intestinal cholesterol uptake by rat intestine in vitro. J. 
Physiol. 1973, 229, 505-514. 
20. Rodgers, J.B.; O'Connor, P.J. Effect of phosphatidylcholine on fatty acid and cholesterol 
absorption from mixed micellar solutions. Biochim. Biophys. Acta 1975, 409, 192-200. 
21. O'Connor, P.J.; Rodgers, J.B. The effect of diether phosphatidylcholine on the enterohepatic 
circulation of biliary sterols. Biochim. Biophys. Acta. 1976, 450, 402-409. 
22. O'Connor, P.J.; Loiudice, T.A.; Bochenek, W.; Rodgers, J.B. Effect of diester and diether 
phosphatidylcholine on intestinal absorption of neutral and acidic sterols. Am. J. Dig. Dis. 1978, 
23, 316-320. 
23. Hollander, D.; Morgan, D. Effect of plant sterols, fatty acids and lecithin on cholesterol 
absorption in vivo in the rat. Lipids 1980, 15, 395-400. 
24.  O'Mullane, J.E.; Hawthorne, J.N. A comparison of the effects of feeding linoleic acid-rich lecithin 
or corn oil on cholesterol absorption and metabolism in the rat. Atherosclerosis 1982, 45, 81-90. 
25.  Jiang, Y.; Noh, S.K.; Koo, S.I. Egg phosphatidylcholine decreases the lymphatic absorption of 
cholesterol in rats. J. Nutr. 2001, 131, 2358-2363. 
26. Noh, S.K.; Koo, S.I. Egg sphingomyelin lowers the lymphatic absorption of cholesterol and 
alpha-tocopherol in rats. J. Nutr. 2003, 133, 3571-3576. 
27.  Noh, S.K.; Koo, S.I. Milk sphingomyelin is more effective than egg sphingomyelin in inhibiting 
intestinal absorption of cholesterol and fat in rats. J. Nutr. 2004, 134, 2611-2616. 
28.  Duivenvoorden, I.; Voshol, P.J.; Rensen, P.C.; van Duyvenvoorde, W.; Romijn, J.A.; Emeis, J.J.; 
Havekes, L.M.; Nieuwenhuizen, W.F. Dietary sphingolipids lower plasma cholesterol and 
triacylglycerol and prevent liver steatosis in APOE*3Leiden mice. Am. J. Clin. Nutr. 2006, 84, 
312-321. 
29.  Beil, F.U.; Grundy, S.M. Studies on plasma lipoproteins during absorption of exogenous lecithin 
in man. J. Lipid Res. 1980, 21, 525-536. Nutrients 2010, 2                              
 
127
30.  Kesaniemi, Y.A.; Grundy, S. M Effects of dietary polyenylphosphatidylcholine on metabolism of 
cholesterol and triglycerides in hypertriglyceridemic patients. Am. J. Clin. Nutr. 1986, 43, 98-107. 
31. Greten, H.; Raetzer, H.; Stiehl, A.; Schettler, G. The effect of polyunsaturated phosphatidyl-
choline on plasma lipids and fecal sterol excretion. Atherosclerosis 1980, 36, 81-88. 
32. Vuoristo, M.; Vaananen, H.; Miettinen, T.A. Cholesterol malabsorption in pancreatic 
insufficiency: effects of enzyme substitution. Gastroenterology 1992, 102, 647-655. 
33.  Hui, D.Y.; Howles, P.N. Carboxyl ester lipase: structure-function relationship and physiological 
role in lipoprotein metabolism and atherosclerosis. J. Lipid Res. 2002, 43, 2017-2030. 
34. Homan, R.; Hamelehle, K.L. Phospholipase A2 relieves phosphatidylcholine inhibition of 
micellar cholesterol absorption and transport by human intestinal cell line Caco-2. J. Lipid Res. 
1998, 39, 1197-1209. 
35.  Mackay, K.; Starr, J.R.; Lawn, R.M.; Ellsworth, J.L. Phosphatidylcholine hydrolysis is required 
for pancreatic cholesterol esterase- and phospholipase A2-facilitated cholesterol uptake into 
intestinal Caco-2 cells. J. Biol. Chem. 1997, 272, 13380-13389. 
36.  Hernell, O.; Staggers, J.E.; Carey, M.C. Physical-chemical behavior of dietary and biliary lipids 
during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal 
lipids during duodenal fat digestion in healthy adult human beings. Biochemistry  1990,  29,  
2041-2056. 
37.  Cohen, D.E.; Carey, M.C. Acyl chain unsaturation modulates distribution of lecithin molecular 
species between mixed micelles and vesicles in model bile. Implications for particle structure and 
metastable cholesterol solubilities. J. Lipid Res. 1991, 32, 1291-1302. 
38. van Erpecum, K.J.; Carey, M.C. Influence of bile salts on molecular interactions between 
sphingomyelin and cholesterol: relevance to bile formation and stability. Biochim. Biophys. Acta. 
1997, 1345, 269-282. 
39. Eckhardt, E.R.; Wang, D.Q.; Donovan, J.M.; Carey, M.C. Dietary sphingomyelin suppresses 
intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers. 
Gastroenterology 2002, 122, 948-956. 
40.  Nyberg, L.; Duan, R.D.; Nilsson, A. A mutual inhibitory effect on absorption of sphingomyelin 
and cholesterol. J. Nutr. Biochem. 2000, 11, 244-249. 
41. Quinn, P.J.; Wolf, C. The liquid-ordered phase in membranes. Biochim. Biophys. Acta 2009, 
1788, 33-46. 
42. Dowhan, W.; Bogdanov, M. Lipid-dependent membrane protein topogenesis. Annu. Rev. 
Biochem. 2009, 78, 515-540. 
43.  Knuiman, J.T.; Beynen, A.C.; Katan, M.B. Lecithin intake and serum cholesterol. Am. J. Clin. 
Nutr. 1989, 49, 266-268. 
44.  Cohn, J.S.; Wat, E.; Kamili, A.; Tandy, S. Dietary phospholipids, hepatic lipid metabolism and 
cardiovascular disease. Curr. Opin. Lipidol. 2008, 19, 257-262. 
 
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 